- Home
- DRMA vs MBIO Comparison
DRMA vs MBIO Comparison
Compare DRMA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- MBIO
- Stock Information
- Founded
- DRMA 2014
- MBIO 2015
- Country
- DRMA United States
- MBIO United States
- Employees
- DRMA N/A
- MBIO N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- MBIO Health Care
- Exchange
- DRMA Nasdaq
- MBIO Nasdaq
- Market Cap
- DRMA 4.5M
- MBIO 4.7M
- IPO Year
- DRMA 2021
- MBIO N/A
- Fundamental
- Price
- DRMA $0.71
- MBIO $2.65
- Analyst Decision
- DRMA Strong Buy
- MBIO
- Analyst Count
- DRMA 1
- MBIO 0
- Target Price
- DRMA $3.00
- MBIO N/A
- AVG Volume (30 Days)
- DRMA 118.5K
- MBIO 17.4M
- Earning Date
- DRMA 08-06-2025
- MBIO 08-12-2025
- Dividend Yield
- DRMA N/A
- MBIO N/A
- EPS Growth
- DRMA N/A
- MBIO N/A
- EPS
- DRMA N/A
- MBIO N/A
- Revenue
- DRMA N/A
- MBIO N/A
- Revenue This Year
- DRMA N/A
- MBIO N/A
- Revenue Next Year
- DRMA N/A
- MBIO N/A
- P/E Ratio
- DRMA N/A
- MBIO N/A
- Revenue Growth
- DRMA N/A
- MBIO N/A
- 52 Week Low
- DRMA $0.57
- MBIO $0.89
- 52 Week High
- DRMA $5.00
- MBIO $24.00
- Technical
- Relative Strength Index (RSI)
- DRMA 53.74
- MBIO 61.22
- Support Level
- DRMA $0.61
- MBIO $2.62
- Resistance Level
- DRMA $0.74
- MBIO $3.68
- Average True Range (ATR)
- DRMA 0.06
- MBIO 0.59
- MACD
- DRMA 0.01
- MBIO 0.18
- Stochastic Oscillator
- DRMA 67.43
- MBIO 28.77
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.